Mechanistic interrogation of combination bevacizumab/dual PI3K/mTOR inhibitor response in glioblastoma implementing novel MR and PET imaging biomarkers.

Philip O'Halloran,Thomas Viel,David W. Murray,Lydia Wachsmuth,Katrin Schwegmann,Stefan Wagner,Klaus Kopka,Monika Jarzabek,Patrick Dicker,Sven Hermann,Cornelius Faber,Tim Klasen,Michael Schäfers,David O’Brien,Jochen H. M. Prehn,Andreas H. Jacobs,Annette T. Byrne

Mechanistic interrogation of combination bevacizumab/dual PI3K/mTOR inhibitor response in glioblastoma implementing novel MR and PET imaging biomarkers.

2016

Philip O'Halloran
Thomas Viel
David W. Murray
Lydia Wachsmuth
Katrin Schwegmann
Stefan Wagner
Klaus Kopka
Monika Jarzabek
Patrick Dicker
Sven Hermann
Cornelius Faber
Tim Klasen
Michael Schäfers
David O’Brien
Jochen H. M. Prehn
Andreas H. Jacobs
Annette T. Byrne

Purpose Resistance to bevacizumab (BEV) in glioblastoma is believed to occur via activation of molecular networks including the mTOR/PI3K pathway. Using an MR/PET molecular imaging biomarker approach, we investigated the response to combining BEV with the mTOR/PI3K inhibitor BEZ235.

Keywords:

Bevacizumab
Discovery and development of mTOR inhibitors
Pathology
Medicine
Glioblastoma
Positron emission tomography
PI3K/AKT/mTOR pathway
Magnetic resonance imaging
Molecular imaging
Biomarker (medicine)
pet imaging

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations